All News
Kirby et al @colmkirby22 . Subclinical GCA in newly diagnosed PMR. 25 patients. 20% had LVV on US - TA in all, axillary in 1. All 5 developed clinical GCA over 1 year. @rheumnow #ACR22 Abstr#0478 https://t.co/xMMjH2XCUD https://t.co/JEtwEGTEbP
Richard Conway RichardPAConway ( View Tweet)
Papo et al. EGPA. Predictors of relapse: Age at diagnosis GC dependent asthma before EGPA (HR1.57), Arthralgia(HR 1.27),myocarditis(HR1.74),peripheral neuropathy(HR 1.39) MPO-ANCA(HR1.56), baseline eosinophil count @rheumnow #ACR22 Abstr#0432 https://t.co/Yq6Eomr9z0 https://t.co/8CYOYROi72
Richard Conway RichardPAConway ( View Tweet)
Genicular nerve block for knee OA - exciting short-term symptomatic option, great Australian work on the Ignite stage. Looking forward to seeing more!
ABST1892 Shanahan et al @Flinders #ACR22 @RheumNow https://t.co/ssYoXj4wjg
David Liew drdavidliew ( View Tweet)
Ab0373 #ACR22 SpA-U
@ChristianaSiero:
42 pts w/ SpA-r uveitis, 190 attacks
Uveitis more severe: smoking, axial & peripheral involvement, BASDAI>4, HLA-B27+, female, CRP elevation, h/o bilateral ocular involvement
Less severe: shorter disease evolution, nml vit D
@Rheumnow
Eric Dein ericdeinmd ( View Tweet)
Important! Abst#2054 A Novel Treatment Response Measure (TRM) for SLE Clinical Trials is being developed, an international collaboration by clinical-academics, regulatory experts, pt reps, & industry. It will impact how clinical trials will be designed. #ACRbest @rheumnow #ACR22
TheDaoIndex KDAO2011 ( View Tweet)
Be careful what you look for? Serum from 32 ACPA+ Pts and 30 ACPA neg all w #rheumatoidarthritis had multiplexed Ab- screening microarray w 1600+ antibodies. Novel Abs were identified in each group vs healthy controls. What does this mean? #ACR22 abst#0256 @RheumNow @ACRheum https://t.co/mqL8kuUkxY
Janet Pope Janetbirdope ( View Tweet)
#ACR22 @RheumNow how do you approach treatment choices for your PsA pts on TNF inhibitors after first TNFi failure?
Olga Petryna DrPetryna ( View Tweet)
Large Korean study on risk of infections in ankylosing spondylitis patients receiving biologics.
Infection incidence risk 26 events/1000 PY
Resp infection most common, 2nd zoster
Heart disease, high DA, DM, current bDMARD use = risk factors
Abs#0372 @RheumNow #ACR22
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR22 Abstr#1205. Are both mRNA vaccine Pfizer or Moderna equivocal in preventing breakthrough infection in fully vaccinated patients with SARDs? @zach_wallace_md showed comparable effectiveness between the two. We can promote whichever brands to our patients @RheumNow https://t.co/yhjxNE8pr2
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Ab0374 #ACR22 BASDAI during pregnancy:
50 pregnant women w/ AS vs controls
AUC for BASDAI in 1st trimester: 0.74, max value for morning stiffness severity (0.9) & duration (0.8)
In 2nd and 3rd trimester: AUC for fatigue and back pain <0.5, morning stiffness remains 0.8
@RheumNow https://t.co/ZQyB37dDxX
Eric Dein ericdeinmd ( View Tweet)
Happening soon in Terrace Ballroom 2
@RheumNow #acr22 https://t.co/6FMFlPxEHc
Eric Dein ericdeinmd ( View Tweet)
Abs 0135 suggests that JAKi may successful tx for Inflammatory ocular pathology (IOP), including uveitis, epi/scleritis, & peripheral ulcerative keratitis, including after failure of cs/bDMARDs. #ACR22 @RheumNow https://t.co/9EDhtSzj1C https://t.co/0LqssF1P8H
Dr. Rachel Tate uptoTate ( View Tweet)
Early AMPLE study proteomic analysis showed 3 potential biomarkers (ANGPT1, TNFRSF10C, and GIF) for predicting CV risk/RA tx response to ABA vs ADA in Abs 0244. Possible new markers for personalized medicine? Can't wait to see more! #ACR22 @RheumNow https://t.co/QRpjJWzNYH https://t.co/6t6SDbouII
Dr. Rachel Tate uptoTate ( View Tweet)
Abs 0251 shows serum NFATc1 assoc'd w/ lipid panel abnormalities & inc CVD risk in early RA pts. I have so many questions regarding clinical use. This is compelling, especially if we can correlate changes in NFATc1 level with treatments. #ACR22 @RheumNow https://t.co/z0fU5TZAiU
Dr. Rachel Tate uptoTate ( View Tweet)
The Navajo Nation has 1 rheumatologist - equitably they need 19 since #RA is 3 times more prevalent! - Dr. J Mandal #ACR22 @rheumnow https://t.co/QcAVJzd4YY https://t.co/zMuZMtl6KC
TheDaoIndex KDAO2011 ( View Tweet)
BIOBADASER 3.0 registry analysis shows risk of incident cancer in patients with rheumatic diseases and previous malignancy did not differ between TNFi or other b/tsDMARDs. Exciting, real-world data. Abs 0267 #ACR22 @RheumNow https://t.co/vZIN3U0QED https://t.co/EM1xXOv0Yd
Dr. Rachel Tate uptoTate ( View Tweet)
Alternate-day GC in IgG4-RD reduced GC-related AEs (adjusted for cumulative GC doses) w/o increase in dz flares particularly when combined w/ immunosuppressants. Possible new tx strategy for clinic? Need more data re: long-term dz Abs 0128 #ACR22 @RheumNow https://t.co/a1c1ZDeOCK https://t.co/3deUugpcVW
Dr. Rachel Tate uptoTate ( View Tweet)
CAR-T cells in #sle - talk of the town this year!
reset the immune system?
deep depletion CD19+ B cell and tissue plasmablasts.
5 pts with SLE - drug free remission at 8 months.
Costs and risks still limiting use widely.
year in review #ACR22 @rheumnow https://t.co/ophgPjCDuF
Bella Mehta bella_mehta ( View Tweet)
Data from - CARRA registry sJIA-Lung Disease cohort -
Affects 1 in 20 pts - Interstitial lung disease (ILD) and pulmonary alveolar proteinosis (PAP).
13 pts - common features - tachypnea, clubbing, cough, finger and toe erythema
#MAS in 56% pts.
@RheumNow #ACR22 abst#0864 https://t.co/Q8fEzOkjJ7
Bella Mehta bella_mehta ( View Tweet)
Sode et al Mortality in GCA. Dominated by CV disease and higher than controls. Less cancer than controls @rheumnow #ACR22 Abstr#0467 https://t.co/TsfTWFRxJ2 https://t.co/lCZgVTpKUY
Richard Conway RichardPAConway ( View Tweet)